Loading... Please wait...

Call 408-734-3800 / Toll Free 877-272-7241


CPC Scientific News & Events

CPC Scientific Inc. and UNC Lineberger Comprehensive Cancer Center Announce Neoantigen Peptide Collaboration to Manufacture Neoantigen Peptides for the PANDA (Personalized and Adaptive) Cancer Vaccine Program.

SUNNYVALE, California, Feb. 19, 2019 – CPC Scientific Inc., a leading global CDMO specializing in synthetic peptide manufacturing, announced today that they will manufacture GMP-grade neoantigen peptides..

Learn More »

Matched-pair, 86Y/90Y-labeled, bivalent RGD/bombesin antagonist,[RGD-Glu-[DO3A]-6-Ahx-RM2], as a potential theranostic agent for prostate cancer.

Bandara, Nilantha, et al. Nuclear Medicine and Biology 62 (2018): 71-77.

Learn More »

7th CPC Symposium on Peptide Therapeutics

Hangzhou, China 10/16/19 – 10/18/2019

Join CPC Scientific at CPhi North America - April 24-26

Attending CPhi? Meet our team at booth #472 in Philadelphia to discuss your peptide needs.

Peptoid ligands that selectively bind receptor CXCR7

Macrocyclic peptoids offer advantages over some small molecule drugs because of their receptor selectivity, potency, and reduced off-target activity. Researchers from Pfizer, UC Santa Cruz, UCSF, and Circle Pharma have developed.. Learn More »

USP7 small-molecule inhibitors interfere with ubiquitin binding.

The ubiquitin system regulates essential cellular processes in eukaryotes. Ubiquitin is ligated to substrate proteins as monomers or chains and the topology of ubiquitin modifications regulates substrate interactions with specific proteins. Thus ubiquitination directs a variety of substrate fates including proteasomal degradation.. Learn More »

TIDES: Oligonucleotide and Peptide Therapeutics - May 7-10

Join CPC Scientific in Boston for the TIDES conference. Meet us at Booth #208! Learn More »

CPC Scientific successfully passes 4th US FDA Inspection.

CPC Scientific is pleased to announce that the CPC Good Manufacturing Practice (GMP) facility in Hangzhou, China has successfully passed its fourth U.S. Food and Drug Administration (FDA) inspection. No Form 483 observations were issued. Learn More »

Peptide Research & Therapeutics News